Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Other Non-Current Assets (2016 - 2026)

Aytu Biopharma has reported Other Non-Current Assets over the past 13 years, most recently at $738000.0 for Q4 2025.

  • Quarterly Other Non-Current Assets changed N/A to $738000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $738000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, 44.9% down from the prior year.
  • Other Non-Current Assets was $738000.0 for Q4 2025 at Aytu Biopharma, down from $939000.0 in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $2.5 million in Q2 2023 and troughed at $457000.0 in Q4 2021.
  • The 5-year median for Other Non-Current Assets is $859000.0 (2022), against an average of $1.1 million.
  • Year-over-year, Other Non-Current Assets soared 4596.97% in 2021 and then tumbled 52.36% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $457000.0 in 2021, then surged by 79.65% to $821000.0 in 2022, then grew by 10.48% to $907000.0 in 2023, then surged by 117.31% to $2.0 million in 2024, then tumbled by 62.56% to $738000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Other Non-Current Assets are $738000.0 (Q4 2025), $939000.0 (Q3 2025), and $1.2 million (Q2 2025).